Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR3 | P49019 | 3/20 | 0.68 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.68 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.63 |
| ▸ | MAPT | P10636 | 5/20 | 0.63 |
| ▸ | RAB9A | P51151 | 2/20 | 0.63 |
| ▸ | NPC1 | O15118 | 1/20 | 0.63 |
| ▸ | PKM | P14618 | 1/20 | 0.63 |
| ▸ | CRHBP | P24387 | 1/20 | 0.63 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.63 |
| ▸ | LMNA | P02545 | 4/20 | 0.61 |
| ▸ | POLB | P06746 | 3/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.61 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
| ▸ | MEN1 | O00255 | 2/20 | 0.51 |
| ▸ | THRB | P10828 | 2/20 | 0.51 |
| ▸ | PPARG | P37231 | 2/20 | 0.51 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.51 |
| ▸ | VDR | P11473 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15319505 | 1.00 | HCAR3 (0.68) | HCAR3ALOX15KMT2AALDH1A1MAPT | |
| SCHEMBL15320045 | 1.00 | HCAR3 (0.68) | HCAR3ALOX15KMT2AALDH1A1MAPT | |
| SCHEMBL15320956 | 1.00 | HCAR3 (0.68) | HCAR3ALOX15KMT2AALDH1A1MAPT | |
| SCHEMBL15319810 | 0.99 | HCAR3 (0.70) | HCAR3ALOX15KMT2AALDH1A1MAPT | |
| SCHEMBL15320365 | 0.97 | HCAR3 (0.70) | HCAR3ALOX15KMT2AALDH1A1MAPT | |
| SCHEMBL15321361 | 0.94 | HCAR3 (0.68) | HCAR3ALOX15KMT2AALDH1A1MAPT | |
| SCHEMBL7842728 | 0.94 | ALOX15 (0.80) | HCAR3ALOX15KMT2AALDH1A1MAPT | |
| SCHEMBL7843052 | 0.94 | KMT2A (0.64) | HCAR3ALOX15KMT2AALDH1A1MAPT | |
| SCHEMBL4124929 | 0.91 | ALOX15 (0.65) | HCAR3ALOX15KMT2AALDH1A1MAPT | |
| SCHEMBL4130039 | 0.90 | KMT2A (0.63) | HCAR3ALOX15KMT2AALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10597381-B2 | Compounds, compositions, and methods for modulating ferroptosis and treating excitotoxic disorders | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2020-03-24 | — | — | US | disclosed |
| US-20190135782-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR MODULATING FERROPTOSIS AND TREATING EXCITOTOXIC DISORDERS | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK | 2019-05-09 | — | — | US | disclosed |
| US-10233171-B2 | Compounds, compositions, and methods for modulating ferroptosis and treating excitotoxic disorders | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK | 2019-03-19 | — | — | US | disclosed |
| US-20170233370-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR MODULATING FERROPTOSIS AND TREATING EXCITOTOXIC DISORDERS | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2017-08-17 | — | — | US | disclosed |
| US-9580398-B2 | Compounds, compositions, and methods for modulating ferroptosis and treating excitotoxic disorders | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2017-02-28 | — | — | US | disclosed |
| US-20150079035-A1 | Compounds, Compositions, and Methods For Modulating Ferroptosis and Treating Excitotoxic Disorders | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-03-19 | — | — | US | disclosed |
| WO-2013152039-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR MODULATING FERROPTOSIS AND TREATING EXCITOTOXIC DISORDERS | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2013-10-10 | — | — | WO | disclosed |
| US-8293923-B2 | Indazole derivatives as modulators of interleukin-1 receptor-associated kinase | BIOGEN IDEC MA INC. (US) | 2012-10-23 | — | — | US | disclosed |
| US-20110152260-A1 | Indazole derivatives as modulators of interleukin-1 receptor-associated kinase | BIOGEN IDEC MA INC. (US) | 2011-06-23 | — | — | US | disclosed |
| EP-2061786-A2 | INDAZOLE DERIVATIVES AS MODULATORS OF INTERLEUKIN-1 RECEPTOR-ASSOCIATED KINASE | Biogen Idec MA Inc. (US) | 2009-05-27 | — | — | EP | disclosed |
| EP-1411928-A1 | VIRAL POLYMERASE INHIBITORS | BOEHRINGER INGELHEIM (CANADA) LTD. (CA) | 2004-04-28 | — | — | EP | disclosed |
| EP-1400241-A1 | FUSED CYCLIC COMPOUNDS AND MEDICINAL USE THEREOF | JAPAN TOBACCO INC. (JP) | 2004-03-24 | — | — | EP | disclosed |
| US-20030236251-A1 | Viral polymerase inhibitors | BOEHRINGER INGELHEIM (CANADA) LTD. (CA) | 2003-12-25 | — | — | US | disclosed |
| US-20030232816-A1 | Viral polymerase inhibitors | BOEHRINGER INGELHEIM (CANADA) LTD. (CA) | 2003-12-18 | — | — | US | disclosed |
| EP-1301487-A2 | VIRAL POLYMERASE INHIBITORS | BOEHRINGER INGELHEIM (CANADA) LTD. (CA) | 2003-04-16 | — | — | EP | disclosed |
| US-20030050320-A1 | Fused-ring compounds and use thereof as drugs | JAPAN TOBACCO INC. (JP) | 2003-03-13 | — | — | US | disclosed |
| WO-2003007945-A1 | VIRAL POLYMERASE INHIBITORS | BOEHRINGER INGELHEIM (CANADA) LTD. (CA) | 2003-01-30 | — | — | WO | disclosed |
| US-6479508-B1 | INHIBITOR OF RNA DEPENDENT RNA POLYMERASE ACTIVITY OF THE ENZYME NS5B ENCODED BY HEPATITIS C VIRUS FOR TREATMENT AND PREVENTION OF HEPATITIS C INFECTIONS | BOEHRINGER INGELHEIM (CANADA) LTD. (CA) | 2002-11-12 | — | — | US | disclosed |
| US-6448281-B1 | INHIBITORS OF HEPATITIS C VIRUS REPLICATION; TREATMENT OF HEPATITIS C | BOEHRINGER INGELHEIM (CANADA) LTD. (CA) | 2002-09-10 | — | — | US | disclosed |
| WO-2002004425-A2 | VIRAL POLYMERASE INHIBITORS | BOEHRINGER INGELHEIM (CANADA) LTD. (CA) | 2002-01-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030050320-A1 | Fused-ring compounds and use thereof as drugs | HAVCR2, ZC3HAV1, HLA-C | HCAR3 1642/4885ALOX15 3837/4885KMT2A 3004/4885 |
| US-10597381-B2 | Compounds, compositions, and methods for modulating ferroptosis and treating excitotoxic disorders | AIFM2, GPX1, GPX4 | HCAR3 783/4885ALOX15 93/4885KMT2A 2204/4885 |
| US-20030236251-A1 | Viral polymerase inhibitors | POLR2H, CTDSP1, POLR2E | HCAR3 1749/4885ALOX15 702/4885KMT2A 3632/4885 |
| US-20030232816-A1 | Viral polymerase inhibitors | POLR2H, POLR2E, POLM | HCAR3 1628/4885ALOX15 4597/4885KMT2A 3370/4885 |
| US-20150079035-A1 | Compounds, Compositions, and Methods For Modulating Ferroptosis and Treating Excitotoxic Disorders | AIFM2, GPX1, GPX4 | HCAR3 904/4885ALOX15 86/4885KMT2A 2411/4885 |
| US-20170233370-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR MODULATING FERROPTOSIS AND TREATING EXCITOTOXIC DISORDERS | AIFM2, GPX1, GPX4 | HCAR3 783/4885ALOX15 93/4885KMT2A 2204/4885 |
| US-10233171-B2 | Compounds, compositions, and methods for modulating ferroptosis and treating excitotoxic disorders | AIFM2, GPX1, GPX4 | HCAR3 783/4885ALOX15 93/4885KMT2A 2204/4885 |
| US-20110152260-A1 | Indazole derivatives as modulators of interleukin-1 receptor-associated kinase | IRAK1, IRAK2, IRAK3 | HCAR3 997/4885ALOX15 2687/4885KMT2A 1839/4885 |
| US-20190135782-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR MODULATING FERROPTOSIS AND TREATING EXCITOTOXIC DISORDERS | AIFM2, GPX1, GPX4 | HCAR3 783/4885ALOX15 93/4885KMT2A 2204/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.